Akebia will receive $10M up front, ~$100M in commercial milestones for rights to Vafseo in the EU & Australia along with royalty up to 30% of net sales. Medice has the rights to market & sells Vafseo in the EEA, UK, Switzerland & Australia
Akebia gets the right to develop Vafseo for anemia due to CKD in non-dialysis patients & also retains the rights in other indications. Medice will commercialize Vafseo for both indications in the defined territory if Akebia exercises those rights where Akebia also retains 70% of the net profit margin of any sales of the licensed product
If Akebia decides to develop vadadustat in other indications & looks for a collaboration partner in the territory, Medice has the right of first refusal for an expanded collaboration
Ref: PR Newswire | Image: Akebia
Related News:- Akebia Receives the MHRA’s Approval of Vafseo for Symptomatic Anemia Associated with Chronic Kidney Disease
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
